Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Vaxcyte Inc. (NASDAQ:PCVX) on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc’s (NYSE:PFE) Prevnar 20 (PCV20) in healthy infants.

The company has selected the VAX-24 Mid-dose as the basis for advancing an optimized dose formulation to a potential Phase 3 program.

Pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026, it plans to initiate an infant Phase 3 study with either VAX-24 or VAX-31.

In this Phase 2 study, VAX-24 was well-tolerated and demonstrated a safety profile similar ...